<DOC>
	<DOCNO>NCT02409667</DOCNO>
	<brief_summary>To demonstrate patient pool PASI 90 responder Week 24 secukinumab 300 mg s.c. administer longer dose interval non-inferior secukinumab 300 mg s.c. every 4 week treatment respect maintain PASI 90 response rate Week 52 .</brief_summary>
	<brief_title>Plaque Psoriasis Efficacy Safety With Secukinumab</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Main 1 . Chronic plaquetype psoriasis diagnose least 6 month prior Screening candidate systemic therapy . 2 . Moderate severe psoriasis Baseline evidence : PASI ≥ 10 IGA mod 2011 score 3 high ( base scale 0 4 ) BSA affect plaquetype psoriasis ≥ 10 % . Main 1 . History exposure biologic drug take treatment chronic plaque psoriasis indication include limited antitumor necrosis factor ( TNF ) alpha , anti interleukin ( IL ) 12/23 , antiIL 17A IL 17A receptor ( IL 17AR ) antibody . 2 . History hypersensitivity study drug drug similar chemical class . 3 . Forms psoriasis chronic plaquetype ( eg , pustular , erythrodermic guttate psoriasis ) . 4 . Druginduced psoriasis ( ie , new onset current exacerbation betablockers , calcium channel inhibitor lithium ) . 5 . Ongoing use prohibit psoriasis treatment ( eg , topical systemic corticosteroid , ultraviolet ( UV ) therapy ) . 6 . Ongoing use nonpsoriasis prohibit treatment . Washout period detail protocol adhere . All prior nonpsoriasis concomitant treatment must stable dose detail protocol initiation study drug . 7 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin ( hCG ) laboratory test ( &gt; 5 mIU/mL ) . 8 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study drug 16 week stop study drug . 9 . Active ongoing inflammatory disease psoriasis might confound evaluation benefit secukinumab therapy . 10 . Underlying condition ( include , limited metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious gastrointestinal condition ) , opinion Investigator , significantly immunocompromises patient and/or place patient unacceptable risk receive immunomodulatory therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>plaque , psoriasis</keyword>
</DOC>